InflaRx (IFRX) Cash & Equivalents (2016 - 2026)

InflaRx has disclosed Cash & Equivalents across 11 years of filings, most recently posting $17.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $17.6 million, down 9.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.6 million (down 9.19% YoY), and the FY2025 annual result was $18.7 million, up 308.98% from the prior year.
• Cash & Equivalents came in at $17.6 million for Q1 2026 at InflaRx, down from $18.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $29.5 million in Q1 2022 to a low of $4.6 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $17.5 million (2023), against an average of $17.1 million.
• Across the five-year window, Cash & Equivalents slumped 66.8% in 2024 and soared 308.98% in 2025, its largest moves.
• InflaRx's Cash & Equivalents stood at $16.6 million in 2022, then declined by 17.22% to $13.7 million in 2023, then plunged by 66.8% to $4.6 million in 2024, then jumped by 308.98% to $18.7 million in 2025, then dropped by 5.88% to $17.6 million in 2026.
• The last three Cash & Equivalents figures came in at $17.6 million (Q1 2026), $18.7 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.